17 November 2026 in Cancer Discovery
Adenosquamous carcinoma (ASC) in intrahepatic cholangiocarcinoma (iCCA) has long been considered rare (∼1 to 2%), yet its occurrence portends lethal disease progression. In this study, we identify latent squamous plasticity, a transcriptionally primed yet histology-silent state that is quantifiable by a squamous transition potential (STP) index. Approximately 20% to 30% of patients with iCCA can be classified as STP high and experience ASC-like dismal outcomes. Mechanistically, FOS-like 1 (FOSL1) acts as a plasticity trigger, driving a temporally ordered squamous program by reshaping the chromatin landscape. Additionally, it cooperates with p63 in an enhancer-dependent manner to dysregulate PTGS2/COX-2 expression. The resulting intratumoral prostaglandin (PG) E2 accumulation drives neutrophil-mediated FOXP3-negative type I regulatory T-cell (Tr1) polarization and predisposes STP-high tumors to immunotherapy resistance. Through a drug-repurposing screen, we identify celecoxib as a dual-function agent that counteracts latent squamous plasticity while fostering an immunopermissive state, providing a clinically actionable strategy for squamous-biased iCCA now being evaluated in a phase Ib/II trial (NCT07632235). Significance: Latent squamous plasticity defines a common yet histologically occult high-risk state in iCCA, driven by FOSL1-dependent enhancer reprogramming and coupled to a PGE2-dependent neutrophil–Tr1 immunosuppressive circuit. By integrating STP-based stratification with celecoxib repurposing, this study identifies latent squamous plasticity as a clinically actionable vulnerability to improve iCCA treatment responsiveness.